AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis

Company Overview

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Key Stats

• Today's Range: $14.99 to $15.00
• 50-Day Range: $14.90 to $15.00
• 52-Week Range: $3.06 to $15.00
• Volume: 247,800 shs
• Average Volume: 601,442 shs
• Market Capitalization: $521.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AVEO Stock Analysis - Frequently Asked Questions

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to analyst estimates of $14.29 million. AVEO Pharmaceuticals had a negative net margin of 30.79% and a negative trailing twelve-month return on equity of 81.66%.

When did AVEO Pharmaceuticals' stock split?

Shares of AVEO Pharmaceuticals reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AVEO Pharmaceuticals investors own include Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Alibaba Group (BABA), Meta Platforms (META), Exelixis (EXEL) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 11/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AVEO
• CUSIP: 05358810
• CIK: 1325879
• Web: www.aveooncology.com
• Phone: (617) 400-0101
• Fax: 617-995-4995
• Employees: 114
• Year Founded: 2001

Profitability

• EPS (Most Recent Fiscal Year): ($0.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-53,340,000.00
• Net Margins: -30.79%
• Pretax Margin: -30.79%
• Return on Equity: -81.66%
• Return on Assets: -28.83%

Debt

• Debt-to-Equity Ratio: 0.94
• Current Ratio: 2.37
• Quick Ratio: 2.35

Sales & Book Value

• Annual Sales: $42.29 million
• Price / Sales: 12.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.33 per share
• Price / Book: 11.28

Miscellaneous

• Outstanding Shares: 34,763,000
• Free Float: 33,619,000
• Market Cap: $521.45 million
• Optionable: Optionable
• Beta: 1.00